Fusion of engineered albumin with factor IX Padua extends half‐life and improves coagulant activity
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Haematology"
DOI: 10.1111/bjh.17559
Abstract: The short half‐life of coagulation factor IX (FIX) for haemophilia B (HB) therapy has been prolonged through fusion with human serum albumin (HSA), which drives the neonatal Fc receptor (FcRn)‐mediated recycling of the chimera. However,… read more here.
Keywords: life; padua; fusion; half life ... See more keywords